Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity

Toxicological Sciences

Volumn 118, Issue 1, 2010, Pages 7-18

  Shaw, Patrick J ^a   Ganey, Patricia E ^b   Roth, Robert A ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Adverse drug reaction; Hepatotoxicity; Idiosyncratic; Inflammation; Trovafloxacin

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIODARONE; CHLORPROMAZINE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DICLOFENAC; DRUG METABOLITE; GAMMA INTERFERON; HALOTHANE; HAPTEN; INTERLEUKIN 18; ISONIAZID; JANUS KINASE; MANGANESE SUPEROXIDE DISMUTASE; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANITIDINE; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; SULINDAC; TIENILIC ACID; TOLCAPONE; TROGLITAZONE; TROVAFLOXACIN; TUMOR NECROSIS FACTOR; VALPROIC ACID;

ACETYLATION; ADAPTATION; ADAPTIVE IMMUNITY; B LYMPHOCYTE; BACTERICIDAL ACTIVITY; CALCIUM HOMEOSTASIS; CELL DEATH; CELL INFILTRATION; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; GENE EXPRESSION; GENETIC POLYMORPHISM; HALOTHANE LIVER INJURY; HEMOSTASIS; HEPATITIS; HUMAN; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; IMMUNOGENICITY; INFLAMMATION; INNATE IMMUNITY; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PROBABILITY; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STRESS; T LYMPHOCYTE;

ANIMALS; ANTI-INFECTIVE AGENTS; DISEASE MODELS, ANIMAL; DRUG TOXICITY; DRUG-INDUCED LIVER INJURY; FLUOROQUINOLONES; HUMANS; INFLAMMATION; NAPHTHYRIDINES; STRESS, PHYSIOLOGICAL;

ANIMALIA; MURINAE;

EID: 77958456930     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq168     Document Type: Review

References (99)

1. Aithal, G. P., Ramsay, L., Daly, A. K., Sonchit, N., Leathart, J. B., Alexander, G., Kenna, J. G., Caldwell, J., and Day, C. P. (2004). Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430-1440.
2. Aldridge, J. E., Gibbons, J. A., Flaherty, M. M., Kreider, M. L., Romano, J. A., and Levin, E. D. (2003). Heterogeneity of toxicant response: sources of human variability. Toxicol. Sci. 76, 3-20.
3. Amacher, D. E. (2006). Reactive intermediates and the pathogenesis of adverse drug reactions: the toxicology perspective. Curr. Drug Metab. 7, 219-229.
4. Andrade, R. J., Lucena, M. I., Alonso, A., Garcia-Cortes, M., Garcia-Ruiz, E., Benitez, R., Fernandez, M. C., Pelaez, G., Romero, M., Corpas, R., et al. (2004). HLA class II genotype influences the type of liver injury in druginduced idiosyncratic liver disease. Hepatology 39, 1603-1612.
5. Bemelmans, M. H., Gouma, D. J., and Buurman, W. A. (1993). Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J. Immunol. 150, 2007-2017.
6. Bemelmans, M. H., Gouma, D. J., and Buurman, W. A. (1994). Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 6, 608-615.
7. Bemelmans, M. H., van Tits, L. J., and Buurman, W. A. (1996). Tumor necrosis factor: function, release and clearance. Crit. Rev. Immunol. 16, 1-11.
8. Bernuau, J., Mallet, L., and Benhamou, J. P. (1981). [Hepatotoxicity due to tienilic acid]. Gastroenterol. Clin. Biol. 5, 692-693.
9. Bird, G. L., and Williams, R. (1989). Detection of antibodies to a halothane metabolite hapten in sera from patients with halothane-associated hepatitis. J. Hepatol. 9, 366-373.
10. Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., and Epler, G. R. (1975). Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69, 289-302.
11. Boelsterli, U. A. (2003). Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192, 307-322.
12. Boelsterli, U. A., and Lim, P. L. (2007). Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220, 92-107.
13. Buchweitz, J. P., Ganey, P. E., Bursian, S. J., and Roth, R. A. (2002). Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 300, 460-467.
14. Chen, H. J., Bloch, K. J., and Maclean, J. A. (2000). Acute eosinophilic hepatitis from trovafloxacin. N. Engl. J. Med. 342, 359-360.
15. Cheng, L., You, Q., Yin, H., Holt, M., Franklin, C., and Ju, C. (2009). Effect of polyI: C cotreatment on halothane-induced liver injury in mice. Hepatology 49, 215-226.
16. Choi, S. (2003). Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ 169, 1187.
17. Cunningham, G. (1997). Adverse drug reactions in the elderly and their prevention. Scott. Med. J. 42, 136-137.
18. Dalvie, D. K., Khosla, N., and Vincent, J. (1997). Excretion and metabolism of trovafloxacin in humans. Drug Metab. Dispos. 25, 423-427.
19. De, S. A., and De, S. G. (2001). Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med. Chem. 8, 371-384.
20. Deng, X., Luyendyk, J. P., Ganey, P. E., and Roth, R. A. (2009). Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol. Rev. 61, 262-282.
21. Deng, X., Stachlewitz, R. F., Liguori, M. J., Blomme, E. A., Waring, J. F., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., and Roth, R. A. (2006). Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 319, 1191-1199.
22. Dugan, C. M., Macdonald, A. E., Roth, R. A., and Ganey, P. E. (2010). A mouse model of severe halothane hepatitis based on human risk factors. J. Pharmacol. Exp. Ther. 333, 364-372.
23. Eghtesadi-Araghi, P., Sohrabpour, A., Vahedi, H., and Saberi-Firoozi, M. (2008). Halothane hepatitis in Iran: a review of 59 cases. World J. Gastroenterol. 14, 5322-5326.
24. Fischman, A. J., Babich, J. W., Alpert, N. M., Vincent, J., Wilkinson, R. A., Callahan, R. J., Correia, J. A., and Rubin, R. H. (1997). Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. Clin. Microbiol. Infect. 3, 379.
25. Ganey, P. E., Luyendyk, J. P., Maddox, J. F., and Roth, R. A. (2004). Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem. Biol. Interact. 150, 35-51.
26. Ganey, P. E., Luyendyk, J. P., Newport, S. W., Eagle, T. M., Maddox, J. F., Mackman, N., and Roth, R. A. (2007). Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 46, 1177-1186.
27. Goel, K., Menzies, D., and Cunha, B. A. (1999). Elevated international normalized ratio associated with trovafloxacin. Ann. Intern. Med. 131, 72.
28. Graham, D. J., Green, L., Senior, J. R., and Nourjah, P. (2003). Troglitazoneinduced liver failure: a case study. Am. J. Med. 114, 299-306.
29. Grattagliano, I., Bonfrate, L., Diogo, C. V., Wang, H. H., Wang, D. Q., and Portincasa, P. (2009). Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J. Gastroenterol. 15, 4865-4876.
30. Gurumurthy, P., Krishnamurthy, M. S., Nazareth, O., Parthasarathy, R., Sarma, G. R., Somasundaram, P. R., Tripathy, S. P., and Ellard, G. A. (1984). Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am. Rev. Respir. Dis. 129, 58-61.
31. Haasio, K., Koponen, A., Penttila, K. E., and Nissinen, E. (2002). Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 453, 21-26.
32. He, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J., and Woolf, T. F. (2004). Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32, 639-646.
33. Hofstra, A. H., and Uetrecht, J. P. (1993). Myeloperoxidase-mediated activation of xenobiotics by human leukocytes. Toxicology 82, 221-242.
34. Huang, W., Na, L., Fidel, P. L., and Schwarzenberger, P. (2004). Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190, 624-631.
35. Huang, Y. S. (2007). Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert. Opin. Drug Metab. Toxicol. 3, 1-8.
36. Hunter, E. B., Johnston, P. E., Tanner, G., Pinson, C. W., and Awad, J. A. (1999). Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am. J. Gastroenterol. 94, 2299-2301.
37. Iwasaki, A., and Medzhitov, R. (2010). Regulation of adaptive immunity by the innate immune system. Science 327, 291-295.
38. Kaitin, K. I. (2005). Drug safety withdrawals in the U.S. not linked to speed of FDA approval. Tufts Center for the Study of Drug Development Impact Report 2005 7.
39. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499.
40. Kaplowitz, N., Aw, T. Y., Simon, F. R., and Stolz, A. (1986). Drug-induced hepatotoxicity. Ann. Intern. Med. 104, 826-839.
41. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie, T. A. (2001). Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70.
42. Keller, B. J., Yamanaka, H., and Thurman, R. G. (1992). Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology 71, 49-61.
43. Kimura, A., Naka, T., and Kishimoto, T. (2007). IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. U.S.A. 104, 12099-12104.
44. Kitteringham, N. R., Kenna, J. G., and Park, B. K. (1995). Detection of autoantibodies directed against human hepatic endoplasmic reticulum in sera from patients with halothane-associated hepatitis. Br. J. Clin. Pharmacol. 40, 379-386.
45. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220.
46. Lazarczyk, D. A., Goldstein, N. S., and Gordon, S. C. (2001). Trovafloxacin hepatotoxicity. Dig. Dis. Sci. 46, 925-926.
47. Lee, W. M. (2003). Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485.
48. Li, A. P. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142, 7-23.
49. Lu, J., Roth, R. A., and Ganey, P. E. (2010). Characterization of an inflammatory stress model of amiodarone idiosyncratic hepatotoxicity in rats. Toxicologist 114, 159 (Abstract).
50. Lucena, M. I., Andrade, R. J., Rodrigo, L., Salmeron, J., Alvarez, A., Lopez-Garrido, M. J., Camargo, R., and Alcantara, R. (2000). Trovafloxacininduced acute hepatitis. Clin. Infect. Dis. 30, 400-401.
51. Luyendyk, J. P., Maddox, J. F., Cosma, G. N., Ganey, P. E., Cockerell, G. L., and Roth, R. A. (2003). Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 307, 9-16.
52. Maddox, J. F., Amuzie, C. J., Li, M., Newport, S. W., Sparkenbaugh, E., Cuff, C. F., Pestka, J. J., Cantor, G. H., Roth, R. A., and Ganey, P. E. (2010). Bacterial and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J. Toxicol. Environ. Health A 73, 58-73.
53. Maniar, J. K., Shah, S. R., Verma, R., Kamath, R., Gupte, P., and Maniar, A. (2006). Nevirapine-induced fulminant hepatitis. J. Assoc. Physicians India 54, 957-958.
54. Mariappan, N., Elks, C. M., Fink, B., and Francis, J. (2009). TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction. Free Radic. Biol. Med. 46, 462-470.
55. Michelson, S., and Joho, K. (2000). Drug discovery, drug development and the emerging world of pharmacogenomics: prospecting for information in a datarich landscape. Curr. Opin. Mol. Ther. 2, 651-654.
56. Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., Thorgeirsson, U. P., Timbrell, J. A., Snodgrass, W. R., and Nelson, S. D. (1976). Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann. Intern. Med. 84, 181-192.
57. Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., and Bass, N. M. (2000). Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig. Dis. Sci. 45, 549-553.
58. Mushin, W. W., Rosen, M., and Jones, E. V. (1971). Post-halothane jaundice in relation to previous administration of halothane. Br. Med. J. 3, 18-22.
59. Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., and Park, B. K. (2000). Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 23, 483-507.
60. Nicholson, S. C., Webb, C. D., and Moellering, R. C., Jr. (2002). Antimicrobial-associated acute hepatitis. Pharmacotherapy 22, 794-796.
61. Obermayer-Straub, P., Strassburg, C. P., and Manns, M. P. (2000). Autoimmune hepatitis. J. Hepatol. 32(1 Suppl.), 181-197.
62. Ong, M. M., Latchoumycandane, C., and Boelsterli, U. A. (2007). Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 97, 205-213.
63. Ostapowicz, G., Fontana, R. J., Schiodt, F. V., Larson, A., Davern, T. J., Han, S. H., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947-954.
64. Park, B. K., Coleman, J. W., and Kitteringham, N. R. (1987). Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 36, 581-590.
65. Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1998). Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969-988.
66. Petrescu, I., and Tarba, C. (1997). Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim. Biophys. Acta 1318, 385-394.
67. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., and Breckenridge, A. M. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15-19.
68. Rademaker, M. (2001). Do women have more adverse drug reactions? Am. J. Clin. Dermatol. 2, 349-351.
69. Robin, M. A., Le, R. M., Descatoire, V., and Pessayre, D. (1997). Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol. 26(Suppl. 1), 23-30.
70. Roth, R. A., and Ganey, P. E. (2010). Intrinsic versus idiosyncratic drug-induced hepatotoxicity-two villains or one? J. Pharmacol. Exp. Ther. 332, 692-697.
71. Roth, R. A., Luyendyk, J. P., Maddox, J. F., and Ganey, P. E. (2003). Inflammation and drug idiosyncrasy-is there a connection? J. Pharmacol. Exp. Ther. 307, 1-8.
72. Sanne, I., Mommeja-Marin, H., Hinkle, J., Bartlett, J. A., Lederman, M. M., Maartens, G., Wakeford, C., Shaw, A., Quinn, J., Gish, R. G., et al. (2005). Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. 191, 825-829.
73. Schwab, C. E., and Tuschl, H. (2003). In vitro studies on the toxicity of isoniazid in different cell lines. Hum. Exp. Toxicol. 22, 607-615.
74. Seguin, B., and Uetrecht, J. (2003). The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 3, 235-242.
75. Shainheit, M. G., Smith, P. M., Bazzone, L. E., Wang, A. C., Rutitzky, L. I., and Stadecker, M. J. (2008). Dendritic cell IL-23 and IL-1 production in response to schistosome eggs induces Th17 cells in a mouse strain prone to severe immunopathology. J. Immunol. 181, 8559-8567.
76. Shaw, P. J., Beggs, K. M., Sparkenbaugh, E. M., Dugan, C. M., Ganey, P. E., and Roth, R. A. (2009a). Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol. Sci. 111, 288-301.
77. Shaw, P. J., Ditewig, A. C., Waring, J. F., Liguori, M. J., Blomme, E. A., Ganey, P. E., and Roth, R. A. (2009b). Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol. Sci. 107, 270-280.
78. Shaw, P. J., Fullerton, A. M., Scott, M. A., Ganey, P. E., and Roth, R. A. (2009c). The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol. Appl. Pharmacol. 236, 293-300.
79. Shaw, P. J., Ganey, P. E., and Roth, R. A. (2009d). Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice. J. Pharmacol. Exp. Ther. 330, 72-78.
80. Shaw, P. J., Ganey, P. E., and Roth, R. A. (2009e). Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J. Pharmacol. Exp. Ther. 328, 62-68.
81. Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., and Roth, R. A. (2007). Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol. Sci. 100, 259-266.
82. Shishido, S., Koga, H., Harada, M., Kumemura, H., Hanada, S., Taniguchi, E., Kumashiro, R., Ohira, H., Sato, Y., Namba, M., et al. (2003). Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37, 136-147.
83. Sibbald, B. (2001). Cisapride, before and after: still waiting for ADE-reporting reform. CMAJ. 165, 1370.
84. Sims, J. E., and Smith, D. E. (2010). The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89-102.
85. Stahlmann, R. (2002). Clinical toxicological aspects of fluoroquinolones. Toxicol. Lett. 127, 269-277.
86. Sun, Q., Zhu, R., Foss, F. W., Jr., and Macdonald, T. L. (2007). Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system. Bioorg. Med. Chem. Lett. 17, 6682-6686.
87. Temple, R. J., and Himmel, M. H. (2002). Safety of newly approved drugs: implications for prescribing. JAMA 287, 2273-2275.
88. Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., and Schwartz, L. W. (2002). Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69, 131-138.
89. Uetrecht, J. (2003). Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today 8, 832-837.
90. Uetrecht, J. (2006). Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab. Rev. 38, 745-753.
91. Uetrecht, J. P. (1999). New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12, 387-395.
92. Walgren, J. L., Mitchell, M. D., and Thompson, D. C. (2005). Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361.
93. Waring, J. F., and Anderson, M. G. (2005). Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds. Curr. Opin. Drug Discov. Devel. 8, 59-65.
94. Waring, J. F., Liguori, M. J., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., Stachlewitz, R. F., North, C., Blomme, E. A., and Roth, R. A. (2006). Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 316, 1080-1087.
95. Watanabe, Y., Suzuki, O., Haruyama, T., and Akaike, T. (2003). Interferongamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. J. Cell Biochem. 89, 244-253.
96. Watkins, P. B. (2005). Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 33, 1-5.
97. Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D., Zineh, I., Giacomini, K. M., and Krauss, R. M. (2007). Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916.
98. Williams, D. P., and Park, B. K. (2003). Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov. Today 8, 1044-1050.
99. Zou, W., Devi, S. S., Sparkenbaugh, E., Younis, H. S., Roth, R. A., and Ganey, P. E. (2009). Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol. Sci. 108, 184-193.